MA55064A - Composés utilisés comme inhibiteurs de kinase - Google Patents

Composés utilisés comme inhibiteurs de kinase

Info

Publication number
MA55064A
MA55064A MA055064A MA55064A MA55064A MA 55064 A MA55064 A MA 55064A MA 055064 A MA055064 A MA 055064A MA 55064 A MA55064 A MA 55064A MA 55064 A MA55064 A MA 55064A
Authority
MA
Morocco
Prior art keywords
kinase inhibitors
compounds used
compounds
kinase
inhibitors
Prior art date
Application number
MA055064A
Other languages
English (en)
Inventor
Nicolas Guisot
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1522245.8A external-priority patent/GB201522245D0/en
Priority claimed from GBGB1613945.3A external-priority patent/GB201613945D0/en
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of MA55064A publication Critical patent/MA55064A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA055064A 2015-12-16 2016-12-16 Composés utilisés comme inhibiteurs de kinase MA55064A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522245.8A GB201522245D0 (en) 2015-12-16 2015-12-16 Compounds useful as kinase inhibitors
GBGB1613945.3A GB201613945D0 (en) 2016-08-15 2016-08-15 Compounds useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
MA55064A true MA55064A (fr) 2021-09-29

Family

ID=57590725

Family Applications (2)

Application Number Title Priority Date Filing Date
MA49809A MA49809A1 (fr) 2015-12-16 2016-12-16 Composés utilisés comme inhibiteurs de kinase
MA055064A MA55064A (fr) 2015-12-16 2016-12-16 Composés utilisés comme inhibiteurs de kinase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA49809A MA49809A1 (fr) 2015-12-16 2016-12-16 Composés utilisés comme inhibiteurs de kinase

Country Status (36)

Country Link
US (7) US10695323B2 (fr)
EP (2) EP3782994A1 (fr)
JP (3) JP6731483B2 (fr)
KR (2) KR20210018530A (fr)
CN (9) CN114634447A (fr)
AU (4) AU2016373530B2 (fr)
CA (1) CA3008488C (fr)
CL (1) CL2018001591A1 (fr)
CO (1) CO2018006164A2 (fr)
CR (1) CR20180367A (fr)
CY (1) CY1123561T1 (fr)
DK (1) DK3390395T3 (fr)
EA (1) EA035132B1 (fr)
ES (1) ES2828431T3 (fr)
FI (1) FIC20240004I1 (fr)
FR (1) FR24C1009I1 (fr)
HK (1) HK1263254A1 (fr)
HR (1) HRP20201835T1 (fr)
HU (2) HUE051921T2 (fr)
IL (4) IL285976B2 (fr)
LT (1) LT3390395T (fr)
MA (2) MA49809A1 (fr)
MD (1) MD3390395T2 (fr)
MX (2) MX2021003478A (fr)
NL (1) NL301262I2 (fr)
NZ (1) NZ743553A (fr)
PE (3) PE20220502A1 (fr)
PH (1) PH12018501268A1 (fr)
PT (1) PT3390395T (fr)
RS (1) RS60982B1 (fr)
SG (2) SG10202012498TA (fr)
SI (1) SI3390395T1 (fr)
TN (1) TN2018000213A1 (fr)
UA (2) UA127863C2 (fr)
WO (1) WO2017103611A1 (fr)
ZA (4) ZA201804137B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
AU2016322063A1 (en) 2015-09-16 2018-04-12 Loxo Oncology, Inc. Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
CA3008488C (fr) * 2015-12-16 2023-10-10 Loxo Oncology, Inc. Composes utilises comme inhibiteurs de kinase
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
MX2020010469A (es) * 2018-04-06 2021-04-19 Praxis Biotech LLC Inhibidores del atf6 y sus usos.
WO2019220962A1 (fr) * 2018-05-18 2019-11-21 富士フイルム株式会社 Procédé de production d'un composé 3-difluorométhylpyrazole, procédé de production d'un composé d'acide 3-difluorométhylpyrazole-4-carboxylique, et composé de pyrazolidine
AU2019314302A1 (en) * 2018-07-31 2021-01-28 Loxo Oncology, Inc. Spray-dried dispersions and formulations of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1H-pyrazole-4-carboxamide
WO2021028645A1 (fr) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
WO2021053234A1 (fr) * 2019-09-19 2021-03-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Composés et compositions pour le traitement d'une maladie rénale
CN110724135B (zh) * 2019-11-18 2023-04-28 上海医药工业研究院有限公司 一种艾拉普林中间体及其制备方法
US20230041515A1 (en) * 2019-12-06 2023-02-09 Loxo Oncology, Inc. Dosing of a bruton's tyrosine kinase inhibitor
US20230145305A1 (en) * 2020-03-12 2023-05-11 Fochon Biosciences, Ltd. Compounds useful as kinase inhibitors
TWI809489B (zh) * 2020-09-10 2023-07-21 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
CN112386597B (zh) * 2020-10-15 2022-03-15 天津济坤医药科技有限公司 泽布替尼在制备治疗肺纤维化疾病药物中的应用
WO2022140246A1 (fr) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Procédés et composés destinés à l'autophagie ciblée
WO2022228302A1 (fr) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Composés carboxamides hétéroaromatiques et leur utilisation
BR112023021235A2 (pt) 2021-05-14 2023-12-12 Loxo Oncology Inc Formas cocristalinas de um inibidor da tirosina quinase de bruton
KR20240029070A (ko) * 2021-07-01 2024-03-05 항저우 힐젠 테라퓨틱스 컴퍼니 리미티드 브루톤 티로신 키나아제, 이의 돌연변이체 분해제, 조성물 및 응용
CN115611810A (zh) * 2021-07-16 2023-01-17 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
CA3241069A1 (fr) 2021-12-14 2023-06-22 Adrianus Petrus Antonius De Man Inhibiteurs macrocycliques de btk
WO2023143355A1 (fr) * 2022-01-28 2023-08-03 Hansoh Bio Llc Dérivé d'amide d'azacycle, ses procédés de préparation et ses utilisations médicinales
WO2023174397A1 (fr) * 2022-03-18 2023-09-21 Insilico Medicine Ip Limited Inhibiteurs de kinase inhibitrice de cdc2 spécifique de la tyrosine et de la thréonine associés à une membrane de pyrazole (pkmyt1) et leurs utilisations
CN115894376A (zh) * 2022-12-15 2023-04-04 南京雷正医药科技有限公司 一种芳香族酰胺类化合物、药物组合物及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
NZ517758A (en) 1999-09-17 2004-06-25 Abbott Gmbh & Co Pyrazolopyrimidines useful as therapeutic agents
US6291504B1 (en) * 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
PT2526933E (pt) 2006-09-22 2015-06-23 Pharmacyclics Inc Inibidores da tirosina-quinase de bruton
MX2009003650A (es) * 2006-10-06 2009-04-22 Abbott Lab Nuevos imidazotiazoles e imidazoxazoles.
CA2668286C (fr) 2006-11-03 2014-09-16 Pharmacyclics, Inc. Sonde d'activite de la tyrosine kinase de bruton et son procede d'utilisation
IL295053A (en) 2007-03-28 2022-09-01 Pharmacyclics Llc Broton tyrosine kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ624345A (en) 2008-06-27 2016-07-29 Celgene Avilomics Res Inc 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2009270856B2 (en) 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
CN102105459B (zh) * 2008-07-24 2014-09-10 内尔维阿诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑类
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
EA201890869A3 (ru) 2010-06-03 2019-03-29 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk)
DK2588465T3 (en) * 2010-06-30 2017-05-01 Ironwood Pharmaceuticals Inc SGC stimulators
SI2710005T1 (sl) 2011-05-17 2017-03-31 Principia Biopharma Inc. Zaviralci tirozinske kinaze
US9580427B2 (en) 2011-05-17 2017-02-28 The Regents Of The University Of California Kinase inhibitors
WO2013010136A2 (fr) 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibiteurs de tyrosine kinase de bruton
EP2548877A1 (fr) 2011-07-19 2013-01-23 MSD Oss B.V. Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US20160045503A1 (en) 2012-06-18 2016-02-18 Principia Biopharma Inc. Formulations containing reversible covalent compounds
WO2014022569A1 (fr) 2012-08-03 2014-02-06 Principia Biopharma Inc. Traitement de la sécheresse oculaire
AU2013299557B2 (en) * 2012-08-10 2017-06-22 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Bruton's tyrosine kinase (BTK) inhibitors
GB201214750D0 (en) * 2012-08-17 2012-10-03 Respivert Ltd Compounds
AU2013340345B2 (en) * 2012-11-02 2016-10-27 Pfizer Inc. Bruton's tyrosine kinase inhibitors
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
GB201309085D0 (en) 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
MX2016004030A (es) * 2013-09-30 2016-10-26 Beijing Synercare Pharma Tech Co Ltd Inhibidores sustituidos de nicotinamida de btk y su preparacion y uso en el tratamiento del cancer, inflamacion y enfermedad autoinmune.
WO2015075051A1 (fr) * 2013-11-19 2015-05-28 Universitaet Des Saarlandes Inhibiteurs allostériques de protéines kinases c atypiques
WO2015095099A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Inhibiteurs de btk
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
GB201404987D0 (en) * 2014-03-20 2014-05-07 Redx Pharma Ltd Compounds
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
WO2016120196A1 (fr) 2015-01-28 2016-08-04 Bayer Pharma Aktiengesellschaft Dérivés de 4h-pyrrolo[3,2-c]pyridin-4-one
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
AU2016322063A1 (en) 2015-09-16 2018-04-12 Loxo Oncology, Inc. Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JP6948322B2 (ja) 2015-12-16 2021-10-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Apj受容体のapjアゴニストとしてのヘテロアリールヒドロキシピリミジノン
MX2018007422A (es) 2015-12-16 2018-08-15 Ecolab Usa Inc Composiciones de acido peroxiformico para limpieza por filtracion en membrana.
RS62525B1 (sr) 2015-12-16 2021-11-30 Boehringer Ingelheim Int Bipirazolil derivati korisni za lečenje autoimunih oboljenja
CA3008488C (fr) * 2015-12-16 2023-10-10 Loxo Oncology, Inc. Composes utilises comme inhibiteurs de kinase
US10981858B2 (en) 2015-12-16 2021-04-20 Priostar Pty Ltd Dendrimer and formulations thereof

Also Published As

Publication number Publication date
AU2016373530B2 (en) 2021-01-21
AU2021225161A1 (en) 2021-09-30
CN113603645A (zh) 2021-11-05
HK1263254A1 (zh) 2020-02-21
EP3782994A1 (fr) 2021-02-24
US20180362512A1 (en) 2018-12-20
PH12018501268A1 (en) 2019-02-18
DK3390395T3 (da) 2020-09-28
CN114716381A (zh) 2022-07-08
NL301262I2 (nl) 2024-04-24
ZA201804137B (en) 2022-08-31
PE20220502A1 (es) 2022-04-07
TN2018000213A1 (en) 2019-10-04
BR112018012341A2 (pt) 2018-12-04
CN114573510A (zh) 2022-06-03
SG11201805044WA (en) 2018-07-30
CN114634447A (zh) 2022-06-17
US10342780B2 (en) 2019-07-09
EA201891268A1 (ru) 2018-11-30
HUE051921T2 (hu) 2021-03-29
CA3008488C (fr) 2023-10-10
US20190135762A1 (en) 2019-05-09
KR20210018530A (ko) 2021-02-17
CL2018001591A1 (es) 2018-09-28
JP2022120013A (ja) 2022-08-17
FIC20240004I1 (fi) 2024-03-01
PE20220507A1 (es) 2022-04-07
CY1123561T1 (el) 2022-03-24
US20210093611A1 (en) 2021-04-01
WO2017103611A1 (fr) 2017-06-22
US10464905B2 (en) 2019-11-05
NZ743553A (en) 2022-08-26
AU2021225162A1 (en) 2021-09-30
EP3390395A1 (fr) 2018-10-24
CN113636978A (zh) 2021-11-12
KR102215792B1 (ko) 2021-02-16
JP7419437B2 (ja) 2024-01-22
US11471441B2 (en) 2022-10-18
JP6731483B2 (ja) 2020-07-29
PT3390395T (pt) 2020-11-03
US10695323B2 (en) 2020-06-30
ZA202107471B (en) 2023-03-29
US20200276162A1 (en) 2020-09-03
AU2021201811B2 (en) 2022-01-27
HRP20201835T1 (hr) 2021-01-08
AU2016373530A1 (en) 2018-07-05
AU2021225161B2 (en) 2023-08-03
IL276283B (en) 2021-03-25
ZA202107472B (en) 2023-03-29
SG10202012498TA (en) 2021-01-28
US20220062239A1 (en) 2022-03-03
EP3390395B1 (fr) 2020-09-09
HUS2400003I1 (hu) 2024-03-28
US20230372298A1 (en) 2023-11-23
JP7086140B2 (ja) 2022-06-17
IL259923B (en) 2020-08-31
CN108473481B (zh) 2022-04-19
MX2021003478A (es) 2022-07-25
AU2021225162B2 (en) 2023-08-03
ZA202100544B (en) 2023-06-28
IL281067A (en) 2021-04-29
MX2018007267A (es) 2018-11-09
MD3390395T2 (ro) 2021-02-28
PE20181449A1 (es) 2018-09-12
SI3390395T1 (sl) 2020-11-30
US20190000806A1 (en) 2019-01-03
FR24C1009I1 (fr) 2024-05-24
IL276283A (en) 2020-09-30
US11826351B2 (en) 2023-11-28
AU2021201811A1 (en) 2021-04-22
CN108473481A (zh) 2018-08-31
EA035132B1 (ru) 2020-04-30
IL259923A (en) 2018-07-31
LT3390395T (lt) 2020-11-25
IL281067B (en) 2022-04-01
US10918622B2 (en) 2021-02-16
IL285976B2 (en) 2023-10-01
CN114605327A (zh) 2022-06-10
MA49809A1 (fr) 2021-08-31
RS60982B1 (sr) 2020-11-30
CO2018006164A2 (es) 2018-09-20
CR20180367A (es) 2018-11-12
CA3008488A1 (fr) 2017-06-22
JP2018538307A (ja) 2018-12-27
UA127863C2 (uk) 2024-01-31
IL285976A (en) 2021-10-31
KR20180115261A (ko) 2018-10-22
CN114621146A (zh) 2022-06-14
IL285976B1 (en) 2023-06-01
JP2020172535A (ja) 2020-10-22
ES2828431T3 (es) 2021-05-26
UA122258C2 (uk) 2020-10-12
CN114591242A (zh) 2022-06-07

Similar Documents

Publication Publication Date Title
FR24C1009I1 (fr) Composés utilisés comme inhibiteurs de kinase
MA52119A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA46045A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA45669A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA44860A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA45116A (fr) Composés hétérocycliques comme immunomodulateurs
DK3656769T3 (da) Aryl-phosphor-oxygen-forbindelse som egfr-kinase-inhibitor
MA51229A (fr) Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr
MA44112A (fr) Composés inhibiteurs de kinases se liant à tank
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA42923A (fr) Composés bicycliques comme inhibiteurs mixtes de atx/ca
MA42293A (fr) Composés antibactériens
DK3303348T3 (da) Naphthyridinforbindelser som JAK-kinaseinhibitorer
MA55633A (fr) Salicylamides de spiroheptane et composés associés utilisés comme inhibiteurs de rock
MA41614A (fr) Composés antiviraux
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
MA41677A (fr) Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8
MA41803A (fr) Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques
DK3717488T3 (da) Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
DK3130592T3 (da) ANALOGER AF 4H-PYRAZOLO[1,5-á]BENZIMIDAZOL-FORBINDELSER SOM PARPINHIBITORER
MA50537A (fr) Composés deutérés utilisés comme immunomodulateurs
MA51221A (fr) Composés de pyrazolopyridinone
MA43791A (fr) Composés de carbapénème
ITUA20161990A1 (it) Mangiatoia per avicoltura